Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
The VALIDATE Network: Accelerating Vaccine Development for Tuberculosis, Leishmaniasis, Melioidosis and Leprosy
Vermaak S. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 11 - 25
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY
Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Wajja A. et al, (2018), Wellcome Open Research, 3, 121 - 121
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy
Fletcher HA. et al, (2018), F1000Research, 7, 485 - 485
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Wajja A. et al, (2017), PLOS Neglected Tropical Diseases, 11, e0005440 - e0005440
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
Minhinnick A. et al, (2016), Vaccine, 34, 1412 - 1421
Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
Minhinnick A. et al, (2016), Journal of Infectious Diseases, 213, 824 - 830
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
Sheehan S. et al, (2015), PLOS ONE, 10, e0141687 - e0141687
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
Ndiaye BP. et al, (2015), The Lancet Respiratory Medicine, 3, 190 - 200
The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
Tameris M. et al, (2014), PLoS ONE, 9, e87340 - e87340
Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
Dieye TN. et al, (2013), PLoS ONE, 8, e67177 - e67177
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
Tameris MD. et al, (2013), The Lancet, 381, 1021 - 1028
Capacity building for tuberculosis vaccine clinical trials in South Africa and Senegal
Vermaak S., (2012), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 17, 39 - 39